The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment. Considered a ...

Cutaneous T-cell lymphomas are a group of T-cell related cancers that mainly affect the skin. There are many different treatment options available for Cutaneous T-cell lymphomas with varying degrees ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab ...

NEW YORK — Symptoms of early-stage cutaneous lymphoma (CL) often mimic nonmalignant skin diseases like psoriasis or eczema, leading to common misdiagnoses and missed opportunities for appropriate ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Researchers were able to use a next-generation sequencing assay to not only monitor minimal residual disease (MRD), but also to confirm diagnosis of cutaneous T-cell lymphoma, which can present as ...

At Fred Hutchinson Cancer Center, we surround you with experts who focus completely on cancer, day in and day out. A handful of people form the core of your care team. You have an oncologist who ...